Pfizer not yet prepared to deliver COVID-19 vaccine data Kumar Jeetendra | October 27, 2020 Drugmaker Pfizer Inc said on October 27 that it wasn’t yet ready to release data in the late-stage trial of the COVID-19 vaccine candidate it is growing with Germany’s BioNTech SE. Pfizer’s CEO Albert Bourla has said the company could release data on whether or not the vaccine works as early as this month, but …
Zydus Cadila gets USFDA nod for generic medication Kumar Jeetendra | October 23, 2020 New Delhi, Oct 23 (PTI) Drug firm Zydus Cadila on Friday said it has received approval from the US health regulator to market Albuterol tablets, used to treat shortness of breath caused by breathing problems like asthma. The company has received final approval from the US Food and Drug Administration (USFDA) to market its product, …
USFDA supports remdesivir, first medication to treat Covid-19 patients Kumar Jeetendra | October 23, 2020 Washington: The United States Food and Drug Administration (FDA) has approved Remdesivir for the treatment of coronavirus, Al Jazeera reported citing a statement issued by Gilead Sciences, Inc.. Based on the press release by the company, previously authorised by the FDA for just emergency use to deal with Covid-19 patients, Veklury or Remdesivir is now …
XL-protein and Antlia Bioscience Announce Collaboration to Develop Long-acting Peptide Therapy of Chronic Heart Failure using PASylation® Technology Kumar Jeetendra | October 22, 2020 SAN DIEGO, U.S.A., and FREISING, Germany, October 15, 2020 – Life Science Newswire – Antlia Bioscience, Inc., a privately owned biopharmaceutical company located in San Diego, California, and XL-protein GmbH, a privately owned biopharmaceutical company located in Germany, are pleased to announce a strategic slliance using XL-protein’s proprietary PASylation® technology for plasma half-life extension to …
SB3000 partners with Evaxion biotech to provide rapid scale up for commercial production of corona virus vaccines Kumar Jeetendra | October 21, 2020 Evaxion Biotech A/S has received funding from the Danish Innovation Fund to further develop their AI platform RAVEN to rapidly respond against future corona virus pandemics – from initial discovery to first in human trials in as little as 13 weeks. During those 13 weeks SB3000 intends to develop and validate a tailored μLOT® continuous …
China’s Sinovac is sheltered, says Brazil’s leading research organization Kumar Jeetendra | October 20, 2020 São Paulo’s Butantan Institute, one of Brazil’s leading biomedical research centers, which is carrying out the Stage 3 tests, said the two-dose vaccine, called CoronaVac, was secure in a trial thus far involving 9,000 volunteers. But Butantan manager Dimas Covas said data on how effective the vaccine is will not be published until the trial …
Pfizer, BioNTech start consolidated preliminaries of COVID-19 immunization candidate in Japan Kumar Jeetendra | October 20, 2020 Pfizer Inc and BioNTech SE announced on Tuesday the start in Japan of combined Phase I and Phase II clinical trials of the mRNA vaccine candidate against the coronavirus. Earlier, they had agreed to supply Japan with 120 million doses of their experimental coronavirus vaccine in the first half of 2021. Pfizer, which is developing …
Cipla launches Nintib to treat Idiopathic Pulmonary Fibrosis Kumar Jeetendra | October 20, 2020 Mumbai, India; October 20, 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced that it has launched generic Nintedanib for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Available as 100 mg and 150 mg capsules, it will be marketed under the brand name Nintib. This launch marks yet …
Glenmark Pharma gets USFDA gesture for generic drug Kumar Jeetendra | October 19, 2020 New Delhi, Oct 19 (PTI) Glenmark Pharmaceuticals on Monday said it has received approval by the US health regulator to market Sirolimus pills, an immunosuppressant, in the American market. The company”s US-based subsidiary has received final approval from the US Food and Drug Administration (USFDA) for the item which is a generic version of PF …
Zydus Cadila gets speculative USFDA gesture for generic drug Kumar Jeetendra | October 19, 2020 New Delhi, Oct 19 Drug firm Zydus Cadila on Monday said it has received tentative approval from the US health regulator to advertise Tofacitinib extended-release pills, used to treat ulcerative colitis, in the American market. The company has received tentative approval from the US Food and Drug Administration (USFDA) for the item which is the …
Trial ALS drug shows potential to drag out patient endurance Kumar Jeetendra | October 18, 2020 An experimental medicine that was recently shown to slow the progression of the neurodegenerative disease amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, has now demonstrated the capacity to also prolong patient survival. The findings come from a clinical trial conducted by investigators at the Sean M. Healey & AMG Center for ALS at Massachusetts …
Eli Lilly delays preliminary of antibody drug Donald Trump promoted as COVID-19 ‘cure’ over wellbeing concern Kumar Jeetendra | October 14, 2020 Eli Lilly and Co said on Tuesday the clinical trial of its COVID-19 antibody treatment similar to one taken by US President Donald Trump has been paused due to a safety concern. Trump touted the Lilly drug, along with the antibody treatment from Regeneron Pharmaceuticals Inc that he received for his COVID-19, as compared to …
